Daily Sepsis Research Analysis
Three studies advance sepsis research across clinical care, data-driven phenotyping, and mechanism-based therapy. An RCT in cirrhotics with septic shock suggests earlier SLED may reduce metabolic complications, intradialytic hypotension, and early deaths. Large-scale machine learning identified high-risk ventilated sepsis phenotypes, and mechanistic work shows hepcidin protects against sepsis-associated AKI via Nrf2/GPX4-mediated anti-ferroptosis.
Summary
Three studies advance sepsis research across clinical care, data-driven phenotyping, and mechanism-based therapy. An RCT in cirrhotics with septic shock suggests earlier SLED may reduce metabolic complications, intradialytic hypotension, and early deaths. Large-scale machine learning identified high-risk ventilated sepsis phenotypes, and mechanistic work shows hepcidin protects against sepsis-associated AKI via Nrf2/GPX4-mediated anti-ferroptosis.
Research Themes
- Timing of renal replacement therapy in septic shock with cirrhosis
- Unsupervised machine learning phenotypes in ventilated sepsis
- Ferroptosis-targeted renoprotection via hepcidin (Nrf2/GPX4) in sepsis-associated AKI
Selected Articles
1. Early Versus Late Dialysis in Cirrhosis Patients and Septic Shock (ELDICS Study): A Randomized Controlled Trial (NCT02937961).
In a randomized trial of 50 critically ill cirrhotic patients (most with pneumonia), initiating SLED within 6–12 hours versus waiting for absolute criteria led to earlier dialysis (median 7 vs 24 hours) and signals of improved outcomes, including lower intradialytic hypotension and early deaths. Twenty-eight–day mortality was numerically lower in the early arm (56% vs 76%), suggesting potential benefit that warrants confirmation.
Impact: Addresses a long-standing uncertainty about dialysis timing in cirrhotics with septic shock using randomized evidence, with clinically meaningful endpoints. Could shape renal support strategies in a high-risk population.
Clinical Implications: Consider earlier SLED initiation (within 6–12 hours) in cirrhotics with septic shock and evolving AKI to reduce metabolic complications and possibly mortality, while awaiting larger confirmatory trials.
Key Findings
- Median time to dialysis was 7 hours (IQR 6–8) in early SLED vs 24 hours (18–48) in delayed SLED.
- Twenty-eight–day mortality was numerically lower with early SLED (56%) versus delayed SLED (76%).
- Early SLED reduced metabolic complications, intradialytic hypotension, and early deaths; renal recovery was more frequent.
Methodological Strengths
- Randomized controlled design with prespecified timing thresholds for SLED.
- Clinically relevant outcomes including 28-day mortality and intradialytic hypotension.
Limitations
- Single-center, small sample size (n=50) limits precision and generalizability.
- Unblinded renal support intervention; incomplete reporting of statistical details in abstract.
Future Directions: Multicenter, adequately powered RCTs should confirm mortality benefit, refine patient selection, and compare early SLED with other RRT modalities in cirrhosis-related septic shock.
BACKGROUND AND AIM: Critically ill cirrhotics (CIC) pose a management challenge due to severe metabolic and renal impairment. The ideal timing of initiation of dialysis in acute kidney injury (AKI) in CIC is not known. We aimed to compare the safety and efficacy of early (ED) versus late (LD) initiation of sustained low-efficiency dialysis (SLED) in CIC. METHODS: CIC were randomized to ED (SLED initiated within 6-12 h) or the LD (where SLED was performed when the patient met absolute criteria) group. RESULTS: Fifty CIC (aged 45.2 ± 10 years), 90% males, 87% alcohol-related, 72% with pneumonia admitted to liver ICU were randomized to ED or LD group. Baseline lactate (mg/dL) (2.7 ± 1.8 vs. 3.3 ± 2.1) and SOFA scores (12.9 ± 2.1 vs. 13.7 ± 4.0) were comparable. Median time to dialysis (in hours) was 7 (IQR 6-8) in ED and 24 (18-48) in LD group. Mortality at 28 days (56% vs. 76%; CONCLUSIONS: Timely initiation of dialysis could avert the development or progression of metabolic complications, decrease the incidence of IDH and early deaths in CIC. A higher frequency of recovery of renal functions and reduced AKI-related mortality could be achieved by timely dialysis in CICs.
2. Protective Effect of Hepcidin on Sepsis-Associated Acute Kidney Injury via Activating the Nrf2/GPX4 Signaling Pathway.
Using CLP mice and LPS-injured HK-2 cells, hepcidin reduced kidney injury and inflammation in SAKI by suppressing ferroptosis. Mechanistically, hepcidin promoted Nrf2 nuclear translocation and GPX4 upregulation; the Nrf2 inhibitor ML385 reversed these effects, supporting a causal Nrf2/GPX4 pathway.
Impact: Identifies a mechanistic, targetable pathway—ferroptosis via Nrf2/GPX4—by which hepcidin confers renoprotection in sepsis, offering a rationale for therapeutic modulation.
Clinical Implications: While preclinical, the data suggest hepcidin agonism or Nrf2/GPX4 activation could be explored as adjunctive therapies for SAKI, potentially alongside iron metabolism modulation.
Key Findings
- Hepcidin attenuated SAKI and reduced inflammatory mediators in CLP mice.
- Hepcidin suppressed renal ferroptosis to an extent comparable to Ferrostatin-1.
- Hepcidin promoted Nrf2 nuclear translocation and upregulated GPX4; ML385 abrogated these effects.
Methodological Strengths
- Integrated in vivo (CLP mice) and in vitro (LPS-induced HK-2 cells) models.
- Mechanistic validation using pathway inhibition (ML385) linking Nrf2/GPX4 to phenotypic rescue.
Limitations
- Preclinical study with no human subjects; translational dosing and safety unknown.
- Sample sizes and blinding/randomization details are not specified in the abstract.
Future Directions: Evaluate hepcidin analogs or Nrf2/GPX4 activators in large-animal models and early-phase clinical trials; assess biomarkers of ferroptosis in SAKI patients to guide precision therapy.
BACKGROUND: Hepcidin not only sustains systemic iron homeostasis but also functions as an antimicrobial peptide. During this study, we sought to analyze the ability of hepcidin to protect against sepsis-associated acute kidney injury (SAKI) and elucidated its underlying mechanisms in mediating ferroptotic pathways. METHODS: A SAKI mouse model was created via cecal ligation and puncture (CLP), along with an LPS-induced Human Kidney-2 (HK-2) cell model, to study the protective mechanism of hepcidin against SAKI. Through the analysis of renal injury biomarkers and ferroptosis-related molecules, combined with quantitative detection of nuclear factor-erythroid 2-related factor-2 (Nrf2) nuclear translocation and glutathione peroxidase 4 (GPX4), a regulatory protein of ferroptosis, we uncovered the hepcidin-mediated mechanisms underlying ferroptosis in SAKI. RESULTS: Hepcidin significantly attenuated renal function impairment in mice with SAKI and reduced the sepsis-driven increase in inflammatory mediators. As sepsis was associated with enhanced renal ferroptosis, hepcidin exerted a therapeutic effect by mitigating ferroptosis to a degree comparable with that of the ferroptosis inhibitor Ferrostatin-1 (Fer-1). Furthermore, hepcidin conferred renoprotective effects in SAKI by promoting the nuclear translocation of Nrf2, which in turn mediated the upregulation of the downstream anti-ferroptotic protein GPX4. Importantly, the Nrf2 inhibitor ML385 abrogated both the hepcidin-induced nuclear translocation of Nrf2 and the subsequent increase in GPX4 expression. CONCLUSIONS: Protective effects of hepcidin against SAKI are mediated by the Nrf2/GPX4 ferroptosis pathway, underscoring its therapeutic potential for SAKI.
3. [Early warning method for invasive mechanical ventilation in septic patients based on machine learning model].
Across >22,000 ICU admissions from MIMIC-IV/III, eICU, and a local dataset, unsupervised clustering of first-day SOFA components yielded three reproducible phenotypes in ventilated sepsis. Phenotype I (cardiorespiratory failure) showed higher vasopressor use, acidosis/hypoxia, more bloodstream infections, and the highest 28-day mortality across training, test, and external validation sets.
Impact: Demonstrates robust, externally validated sepsis phenotypes using simple SOFA features, enabling early risk stratification for ventilated patients and setting the stage for phenotype-guided trials.
Clinical Implications: Early identification of phenotype I could prioritize aggressive hemodynamic optimization, infection control, and trial enrollment; SOFA-based clustering is readily implementable using routine ICU data.
Key Findings
- K-means clustering of first-day SOFA components identified three phenotypes with optimal cluster number = 3 by SSE/DBI.
- Phenotype I had severe cardiorespiratory dysfunction, higher vasopressor use, metabolic acidosis/hypoxia, and more congestive heart failure.
- Phenotype I exhibited higher bloodstream culture positivity (Gram-positive, Gram-negative, fungi) and the highest 28-day mortality across datasets.
Methodological Strengths
- Large, multicohort analysis with external validation across MIMIC-III/IV, eICU, and a local dataset.
- Unsupervised learning using readily available SOFA components enables clinical translation.
Limitations
- Retrospective observational design susceptible to residual confounding and data quality issues.
- Clustering based solely on SOFA components may omit informative variables (e.g., lactate kinetics, comorbidity burden).
Future Directions: Prospective validation with real-time implementation and testing phenotype-guided management strategies to determine causal impact on outcomes.
OBJECTIVE: To develop a method for identifying high-risk patients among septic populations requiring mechanical ventilation, and to conduct phenotypic analysis based on this method. METHODS: Data from four sources were utilized: the Medical Information Mart for Intensive Care (MIMIC-IV 2.0, MIMIC-III 1.4), the Philips eICU-Collaborative Research Database 2.0 (eICU-CRD 2.0), and the Anhui Medical University Second Affiliated Hospital dataset. The adult patients in intensive care unit (ICU) who met Sepsis-3 and received invasive mechanical ventilation (IMV) on the first day of first admission were enrolled. The MIMIC-IV dataset with the highest data integrity was divided into a training set and a test set at a 6:1 ratio, while the remaining datasets were served as validation sets. The demographic information, comorbidities, laboratory indicators, commonly used ICU scores, and treatment measures of patients were extracted. Clinical data collected within first day of ICU admission were used to calculate the sequential organ failure assessment (SOFA) score. K-means clustering was applied to cluster SOFA score components, and the sum of squared errors (SSE) and Davies-Bouldin index (DBI) were used to determine the optimal number of disease subtypes. For clustering results, normalized methods were employed to compare baseline characteristics by visualization, and Kaplan-Meier curves were used to analyze clinical outcomes across phenotypes. RESULTS: This study enrolled patients from MIMIC-IV dataset (n = 11 166), MIMIC-III dataset (n = 4 821), eICU-CRD dataset (n = 6 624), and a local dataset (n = 110), with the four datasets showing similar median ages and male proportions exceeding 50%; using 85% of the MIMIC-IV dataset as the training set, 15% as the test set, and the rest dataset as the validation set. K-means clustering based on the six-item SOFA score was performed to determine the optimal number of clusters as 3, and patients were finally classified into three phenotypes. In the training set, compared with the patients with phenotype II and phenotype III, those with phenotype I had the more severe circulatory and respiratory dysfunction, a higher proportion of vasoactive drug usage, more obvious metabolic acidosis and hypoxia, and a higher incidence of congestive heart failure. The patients with phenotype II was dominated by respiratory dysfunction with higher visceral injury. The patients with phenotype III had relatively stable organ function. The above characteristics were consistent in both the test and validation sets. Analysis of infection-related indicators showed that the patients with phenotype I had the highest SOFA score within 7 days after ICU admission, initial decreases and later increases in platelet count (PLT), and higher counts of neutrophils, lymphocytes, and monocytes as compared with those with phenotype II and phenotype III, their blood cultures had a higher positivity rates for Gram-positive bacteria, Gram-negative bacteria and fungi as compared with those with phenotype II and phenotype III. The Kaplan-Meier curve indicated that in the training, test, and validation sets, the 28-day cumulative mortality of patients with phenotype I was significantly higher than that of patients with phenotypes II and phenotype III. CONCLUSIONS: Three distinct phenotypes in septic patients receiving IMV based on unsupervised machine learning is derived, among which phenotype I, characterized by cardiorespiratory failure, can be used for the early identification of high-risk patients in this population. Moreover, this population is more prone to bloodstream infections, posing a high risk and having a poor prognosis.